Business
InMed Provides Update on BayMedica Commercial Business
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement. Recently, H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026" (the "Act") was...
About this update from Inmed Pharmaceuticals Inc.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.","length":344,"tagName":"p"},{"type":"text","content":"Recently, H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026" (the "Act") was signed into law.","length":208,"tagName":"p"},{"type":"text","content":"The Company has been evaluating the impact of the Act with its advisors and believes that the Act, in its current form and without further amendment, will have a material negative impact on BayMedica Inc. ("BayMedica"), a subsidiary of the Company. Specifically, certain aspects of BayMedica's commercial business and its inventory of rare, non-intoxicating cannabinoids would be prohibited under the Act if it comes into force on November 12, 2026, in its current form. BayMedica is evaluating the potential of creating alternative supply chain options in order to maintain continued regulatory compliance.","length":621,"tagName":"p"},{"type":"text","content":"InMed Remains Focused on Core Pharmaceutical Programs","length":53,"tagName":"p"},{"type":"text","content":"Despite the potential impact of the Act on BayMedica's commercial operations, the new legislation does not affect InMed's pharmaceutical drug development programs, which operate within the traditional drug approval pathway under FDA guidance. InMed remains fully committed to advancing its core pharmaceutical business. The Company continues to progress INM-901 for the treatment of Alzheimer's disease and INM-089 for the treatment of age-related macular degeneration (AMD).","length":487,"tagName":"p"},{"type":"text","content":"InMed's Evaluation of Potential Impact of Act on BayMedica","length":62,"tagName":"p"},{"type":"text","content":"It is unknown to the Company whether the sections of the Act that would impact BayMedica will ultimately go into effect on November 12, 2026, or at all, or if those sections will be replaced, impacted or amended by subsequent acts of U.S. policymakers. The Comp...